Mucormycosis - from the pathogens to the disease

Clinical Microbiology and Infection

Volumn 20, Issue 6, 2014, Pages 60-66

  Binder, U ^a   Maurer, E ^a   Lass Florl C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Angioinvasion; Iron overload; Ketoacidosis; Mucorales; Mucormycosis; Risk factors; Zygomycetes

Indexed keywords

DIABETIC KETOACIDOSIS; FUNGAL VIRULENCE; HUMAN; MUCORMYCOSIS; MYCOSIS; NOMENCLATURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TAXONOMY; CLASSIFICATION; MICROBIOLOGY; MUCORALES; PHYSIOLOGY;

VIRULENCE FACTOR;

HUMANS; MUCORALES; MUCORMYCOSIS; RISK FACTORS; VIRULENCE FACTORS;

EID: 84922319400     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12566     Document Type: Review

References (76)

1. Auberger J, Lass-Flörl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother 2012; 67: 2268-2273.
2. Alastruey-Izquierdo A, Hoffmann K, de Hoog GS, et al. Species recognition and clinical relevance of the zygomycetous genus Lichtheimia (syn. Absidia pro parte, Mycocladus). J Clin Microbiol 2010; 48: 2154-2170.
3. Alastruey-Izquierdo A, Castelli MV, Cuesta I, et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 2009; 15: 71-76.
4. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-1867.
5. Kirk PM, Cannon PF, David JC, Stalpers JA. Ainsworth & Bisby's dictionary of the fungi. Wallingford, UK: CAB International, 2001.
6. Hibbett DS, Binder M, BischoffJF, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res, 2007; 111: 509-547.
7. James TY, KauffF, Schoch CL, et al. Reconstructing the early evolution of Fungi using a six-gene phylogeny. Nature 2006; 443: 818-822.
8. Keeling PJ. Congruent evidence from alpha-tubulin and beta-tubulin gene phylogenies for a zygomycete origin of microsporidia. Fungal Genet Biol 2003; 38: 298-309.
9. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54 (suppl 1): S8-S15.
10. Liu YJ, Hodson MC, Hall BD. Loss of the flagellum happened only once in the fungal lineage: phylogenetic structure of kingdom Fungi inferred from RNA polymerase II subunit genes. BMC Evol Biol 2006; 6: 74.
11. Ajello L, Dean DF, Irwin RS. The zygomycete Saksenaea vasiformis as a pathogen of humans with a critical rewiew of the etiology of zygomycosis. Mycologia 1976; 68: 52-62.
12. Kwon-Chung KBJ. Medical mycology. Philadelphia, PA: Lea & Febiger, 1992.
13. De Hoog GS, Guarro J, Gene J, Figueras MJ. Atlas of clinical fungi. Utrecht, The Netherlands: Centraalbureau voor Schimmelcultures, 2011.
14. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-509.
15. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60-66.
16. Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother 2011; 55: 5018-5021.
17. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
18. Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol 2013; 8: 1163-1175.
19. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
20. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395-1401.
21. Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis 2011; 11: 301-311.
22. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-569.
23. Teixeira CA, Medeiros PB, Leushner P, Almeida F. Rhinocerebral mucormycosis: literature review apropos of a rare entity. BMJ Case Rep 2013; doi: 10.1136/bcr-2013-008552.
24. Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med 2011; 32: 693-702.
25. Schofield C, Stern A, Jevtic A. Disseminated zygomycosis due to Mycocladus corymbifera with cutaneous and cerebral involvement. Australas J Dermatol 2013; 54: e8-e11.
26. Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect 2009; 15 (suppl 5): 41-45.
27. Skiada A, Petrikkos G. Cutaneous mucormycosis. Skinmed, 2013; 11: 155-159; quiz 159-60.
28. Geisen M, Fodor P, Eich G, Zollinger A, Dzemali O, Blumenthal S. Disseminated cutaneous mucormycosis in a patient on high-dose steroid therapy for severe ARDS. Intensive Care Med 2011; 37: 1895-1896.
29. Chawla R, Sehgal S, Kumar SR, Mishra B. A rare case of mucormycosis of median sternotomy wound caused by Rhizopus arrhizus. Indian J Med Microbiol 2007; 25: 419-421.
30. Ismail MH, Hodkinson HJ, Setzen G, Sofianos C, Hale MJ. Gastric mucormycosis. Trop Gastroenterol 1990; 11: 103-105.
31. Oliver MR, Van Voorhis WC, Boeckh M, Mattson D, Bowden RA. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996; 22: 521-524.
32. Geramizadeh B, Modjalal M, Nabai S, et al. Gastrointestinal zygomycosis: a report of three cases. Mycopathologia 2007; 164: 35-38.
33. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-273.
34. Petrikkos G, Drogari-Apiranthitou M. Zygomycosis in immunocompromised non-haematological patients. Mediterr J Hematol Infect Dis 2011; 3: e2011012.
35. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (Suppl 1): S23-S34.
36. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against zygomycetes. Clin Infect Dis 2012; 54 (Suppl 1): S61-S66.
37. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982; 31: 1109-1114.
38. Dabritz J, Attarbaschi A, Tintelnot K, et al. Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases. Mycoses 2011; 54: e785-e788.
39. Ibrahim AS. Host cell invasion in mucormycosis: role of iron. Curr Opin Microbiol 2011; 14: 406-411.
40. Waldorf AR, Diamond RD. Cerebral mucormycosis in diabetic mice after intrasinus challenge. Infect Immun 1984; 44: 194-195.
41. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984; 74: 150-160.
42. Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982; 38: 1123-1129.
43. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649-2657.
44. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008; 21: 620-625.
45. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50: 3968-3969.
46. Spellberg B, Andes D, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53: 3122-3125.
47. Rammaert B, Lanternier F, Zahar JR, et al. Healthcare-associated mucormycosis. Clin Infect Dis 2012; 54 (suppl 1): S44-S54.
48. Shetty S, Kini U, Joy R. Isolated lingual mucormycosis in an infant with Down syndrome. Ear Nose Throat J 2008; 87: 43.
49. de Oliveira-Neto MP, Da Silva M, Fialho Monteiro PC, et al. Cutaneous mucormycosis in a young, immunocompetent girl. Med Mycol, 2006; 44: 567-570.
50. Lechevalier P, Hermoso DG, Carol A, et al. Molecular diagnosis of Saksenaea vasiformis cutaneous infection after scorpion sting in an immunocompetent adolescent. J Clin Microbiol 2008; 46: 3169-3172.
51. Pourahmad M, Sepidkar A, Farokhnia MH, Tadayon SM, Salehi H, Zabetian H. Mucormycosis after scorpion sting: case report. Mycoses 2013; 56: 589-591.
52. Saravia-Flores M, Guaran DM, Argueta V. Invasive cutaneous infection caused by Apophysomyces elegans associated with a spider bite. Mycoses 2010; 53: 259-261.
53. Tidwell J, Higuera S, Hollier LH Jr. Facial reconstruction after mucormycosis in an immunocompetent host. Am J Otolaryngol 2005; 26: 333-336.
54. Andresen D, Donaldson A, Choo L, et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet 2005; 365: 876-878.
55. Kouadio IK, Aljunid S, Kamigaki T, Hammad K, Oshitani H. Infectious diseases following natural disasters: prevention and control measures. Expert Rev Anti Infect Ther 2012; 10: 95-104.
56. Neblett Fanfair R, Benedict K, Bos J, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med, 2012; 367: 2214-2225.
57. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2012; 96: 748-757.
58. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-952.
59. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005; 40: 770-771.
60. Lalwani S, Govindasamy M, Gupta M, et al. Gastrointestinal mucormycosis - four cases with different risk factors, involving different anatomical sites. Indian J Gastroenterol 2012; 31: 139-143.
61. Schwartze VU, Hoffmann K, Nyilasi I, et al. Lichtheimia species exhibit differences in virulence potential. PLoS ONE 2012; 7: e40908.
62. Ma LJ, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009; 5: e1000549.
63. Morace G, Borghi E. Invasive mold infections: virulence and pathogenesis of mucorales. Int J Microbiol 2012; 2012: 349278.
64. Schrettl M, Haas H. Iron homeostasis - Achilles' heel of Aspergillus fumigatus? Curr Opin Microbiol 2011; 14: 400-405.
65. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91: 1979-1986.
66. Ibrahim AS, Gebremariam T, Lin L, et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010; 77: 587-604.
67. Symeonidis AS. The role of iron and iron chelators in zygomycosis. Clin Microbiol Infect 2009; 15 (Suppl 5): 26-32.
68. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005; 73: 778-783.
69. Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120: 1914-1924.
70. Levitz SM, Selsted ME, Ganz T, Lehrer RI, Diamond RD. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis 1986; 154: 483-489.
71. Netea MG, Ferwerda G, van der Graaf CA, Van der Meer JW, Kullberg BJ. Recognition of fungal pathogens by toll-like receptors. Curr Pharm Des 2006; 12: 4195-4201.
72. Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin Microbiol Infect 2006; 12: 404-409.
73. Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 2008; 52: 722-724.
74. van de Veerdonk FL, Kullberg BJ, van der Meer JW, Gow NA, Netea MG. Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol 2008; 11: 305-312.
75. Warris A, Netea MG, Verweij PE, et al. Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to Aspergillus fumigatus and other filamentous fungi. Med Mycol 2005; 43: 613-621.
76. Cortez KJ, Lyman CA, Kottilil S, et al. Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus. Infect Immun 2006; 74: 2353-2365.